Veru Inc. (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders [Yahoo! Finance]
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
Veru Inc. (NASDAQ: VERU) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek